vs
Akebia Therapeutics, Inc.（AKBA）与万物新生（RERE）财务数据对比。点击上方公司名可切换其他公司
Akebia Therapeutics, Inc.的季度营收约是万物新生的1.3倍（$57.6M vs $43.2M）
Akebia Therapeutics是一家专注于肾病领域的生物制药企业，核心业务覆盖药物研发、临床试验及商业化推广全流程，主要开发针对慢性肾病相关贫血等适应症的创新疗法，面向全球市场，致力于满足肾病治疗领域未被满足的临床需求。
万物新生集团（ATRenew Inc.）是中国领先的二手消费电子产品交易与服务平台运营商，核心业务覆盖数码产品回收、质检、翻新及售卖，运营有爱回收等知名品牌，服务覆盖个人消费者及企业客户，市场遍及国内及部分东南亚地区。
AKBA vs RERE — 直观对比
营收规模更大
AKBA
是对方的1.3倍
$43.2M
损益表 — Q4 FY2025 vs Q1 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $57.6M | $43.2M |
| 净利润 | — | $7.3M |
| 毛利率 | 78.2% | — |
| 营业利润率 | -14.8% | — |
| 净利率 | — | 16.9% |
| 营收同比 | 23.9% | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AKBARERE
| Q4 25 | $57.6M | — | ||
| Q3 25 | $58.8M | — | ||
| Q2 25 | $62.5M | — | ||
| Q1 25 | $57.3M | — | ||
| Q4 24 | $46.5M | — | ||
| Q3 24 | $37.4M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $32.6M | — |
净利润AKBARERE
| Q4 25 | — | — | ||
| Q3 25 | $540.0K | — | ||
| Q2 25 | $247.0K | — | ||
| Q1 25 | $6.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-20.0M | — | ||
| Q2 24 | $-8.6M | — | ||
| Q1 24 | $-18.0M | — |
毛利率AKBARERE
| Q4 25 | 78.2% | — | ||
| Q3 25 | 84.0% | — | ||
| Q2 25 | 84.1% | — | ||
| Q1 25 | 86.7% | — | ||
| Q4 24 | 56.2% | — | ||
| Q3 24 | 62.2% | — | ||
| Q2 24 | 60.9% | — | ||
| Q1 24 | 64.4% | — |
营业利润率AKBARERE
| Q4 25 | -14.8% | — | ||
| Q3 25 | 7.6% | — | ||
| Q2 25 | 22.6% | — | ||
| Q1 25 | 23.6% | — | ||
| Q4 24 | -30.8% | — | ||
| Q3 24 | -33.4% | — | ||
| Q2 24 | -20.0% | — | ||
| Q1 24 | -45.8% | — |
净利率AKBARERE
| Q4 25 | — | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 10.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -53.5% | — | ||
| Q2 24 | -19.7% | — | ||
| Q1 24 | -55.2% | — |
每股收益（稀释后）AKBARERE
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $-0.10 | — | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $184.8M | $228.0M |
| 总债务越低越好 | $48.3M | — |
| 股东权益账面价值 | $32.6M | $557.1M |
| 总资产 | $376.6M | $722.9M |
| 负债/权益比越低杠杆越低 | 1.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AKBARERE
| Q4 25 | $184.8M | — | ||
| Q3 25 | $166.4M | — | ||
| Q2 25 | $137.3M | — | ||
| Q1 25 | $113.4M | — | ||
| Q4 24 | $51.9M | — | ||
| Q3 24 | $34.0M | — | ||
| Q2 24 | $39.5M | — | ||
| Q1 24 | $42.0M | — |
总债务AKBARERE
| Q4 25 | $48.3M | — | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $47.1M | — | ||
| Q1 25 | $46.5M | — | ||
| Q4 24 | $38.7M | — | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | $38.0M | — | ||
| Q1 24 | $30.1M | — |
股东权益AKBARERE
| Q4 25 | $32.6M | — | ||
| Q3 25 | $41.6M | — | ||
| Q2 25 | $29.2M | — | ||
| Q1 25 | $24.6M | — | ||
| Q4 24 | $-49.2M | — | ||
| Q3 24 | $-50.4M | — | ||
| Q2 24 | $-33.8M | — | ||
| Q1 24 | $-27.3M | — |
总资产AKBARERE
| Q4 25 | $376.6M | — | ||
| Q3 25 | $364.2M | — | ||
| Q2 25 | $345.6M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | $220.7M | — | ||
| Q3 24 | $207.1M | — | ||
| Q2 24 | $220.2M | — | ||
| Q1 24 | $225.5M | — |
负债/权益比AKBARERE
| Q4 25 | 1.48× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.61× | — | ||
| Q1 25 | 1.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.1M | — |
| 自由现金流经营现金流 - 资本支出 | $31.1M | — |
| 自由现金流率自由现金流/营收 | 53.9% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $67.7M | — |
8季度趋势，按日历期对齐
经营现金流AKBARERE
| Q4 25 | $31.1M | — | ||
| Q3 25 | $28.1M | — | ||
| Q2 25 | $22.3M | — | ||
| Q1 25 | $-13.6M | — | ||
| Q4 24 | $-4.5M | — | ||
| Q3 24 | $-6.7M | — | ||
| Q2 24 | $-10.1M | — | ||
| Q1 24 | $-19.4M | — |
自由现金流AKBARERE
| Q4 25 | $31.1M | — | ||
| Q3 25 | $28.0M | — | ||
| Q2 25 | $22.2M | — | ||
| Q1 25 | $-13.6M | — | ||
| Q4 24 | $-4.5M | — | ||
| Q3 24 | $-6.7M | — | ||
| Q2 24 | $-10.1M | — | ||
| Q1 24 | — | — |
自由现金流率AKBARERE
| Q4 25 | 53.9% | — | ||
| Q3 25 | 47.7% | — | ||
| Q2 25 | 35.6% | — | ||
| Q1 25 | -23.7% | — | ||
| Q4 24 | -9.6% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -23.1% | — | ||
| Q1 24 | — | — |
资本支出强度AKBARERE
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.0% | — |
现金转化率AKBARERE
| Q4 25 | — | — | ||
| Q3 25 | 52.05× | — | ||
| Q2 25 | 90.47× | — | ||
| Q1 25 | -2.22× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AKBA
| Auryxia | $48.1M | 84% |
| Vafseo | $6.2M | 11% |
| License Collaboration And Other Revenue | $3.3M | 6% |
RERE
暂无分部数据
